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Nonalcoholic Fatty Liver Disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is a marker of Insulin
Resistance (IR). Euglycemic-hyperinsulinemic clamp is the gold standard for measuring whole body IR (hepatic + peripheral
IR). However, it is an invasive and expensive procedure. Homeostasis Model Assessment Index for Insulin Sensitivity (HOMA-IS),
Quantitative Insulin Sensitivity Check Index (QUICKI) for hepatic IR and Insulin Sensitivity Index (ISI0,120), and Whole Body
Insulin Sensitivity Index (WBISI) for whole body IR are the indices calculated after Oral Glucose Tolerance Test (OGTT). We used
theseindicesasnoninvasivemethodsofIR(inverseofinsulinsensitivity)estimationandcomparedhepatic/peripheralcomponents
of whole body IR in NAFLD. Methods. 113 morbidly obese, nondiabetic subjects who underwent gastric bypass surgery and
intraoperative liver biopsy were included in the study. OGTT was performed preoperatively and the indices were calculated.
Subjects were divided into closely matched groups as normal, fatty liver (FL) and Non-Alcoholic Steatohepatitis (NASH) based on
histology. Results. Whole body IR was signiﬁcantly higher in both FL and NASH groups (NAFLD) as compared to Normal, while
hepatic IR was higher only in NASH from Normal. Conclusions. FL is a manifestation of peripheral IR but not hepatic IR.
1.Introduction
NAFLD is the term used for the spectrum of hepatic
pathology ranging from simple steatosis to steatohepatitis
and cirrhosis in individuals who do not consume alcohol in
amount which is generally considered harmful to the liver.
In simple steatosis, fat accumulates in the hepatocytes called
FL, which is seen in up to 30% of general and 75% of obese
individuals. Development of FL has been reported to be
associated with BMI, abnormal glucose tolerance, IR, and
other components of MetS [1]. Hepatocytes with excessive
intracellular fat “ﬁrst hit” create a state of oxidative stress
andpossiblywithaccumulationofoxidativedamage“second
hit” FL may progress to NASH which is present in 5% of
the general population and 20% of obese subjects [2, 3].
NASH may further progress to advanced ﬁbrosis, cirrhosis,
and hepatocellular carcinoma [4].
NAFLD is considered a hepatic complication of MetS.
Studies have documented close relationship between MetS,
NAFLD, and IR but the underlying mechanisms have not
beenclariﬁed[1,5].Postabsorptivephasehyperglycemiaand
subsequent hyperinsulinemia are believed to be important
physiologic risk factors for hepatocyte injury and progressive
hepatic ﬁbrosis [6, 7]. These metabolic derangements are
ampliﬁed in setting of IR. IR can be deﬁned as altered
metabolic condition in which higher than normal insulin
levels are needed to achieve normal metabolic responses.
IR—the reciprocal of insulin sensitivity, is present long2 Journal of Obesity
before the DM become clinically manifest. IR can be central
(hepatic) or peripheral (muscle, fat) depending upon the
primary site of involvement. Peripheral IR impairs glucose
uptake from blood into muscles (Postabsorptive and fasting
states) while hepatic IR manifests as unrestrained glucose
productionbyliverunderfastingconditions[8].Wholebody
IR is a composite of hepatic and peripheral IR and is best
measured by euglycemic-hyperinsulinemic clamp technique
[9] .T h em e t h o di si n v a s i v ea n dc a n n o tb ed o n eo nl a r g e r
populations onroutinebasis.Severalauthorshavedeveloped
simpler methods and indices based on various weighted
combinations of glucose and insulin levels at fasting or dur-
ingOGTT.Indicesrelyinguponsinglefastingbloodsamples,
such as homeostatic model assessment (HOMA) [10]a n d
quantitative insulin sensitivity check index (QUICKI) [11]
are widely used in general population for their simplicity
for accessing hepatic IR. Several other more comprehensive
approachesof non-invasive estimation of IR have been tested
in several populations, which use Postabsorptive insulin and
glucose levels in addition to fasting ones and provide more
elaborative and physiologic assessment of IR. Two of such
methods are Insulin Sensitivity Index (ISI0,120)[ 12, 13]a n d
Whole Body Insulin Sensitivity Index (WBISI) [14]w h i c h
have also been validated as reliable indices of whole body
insulin sensitivity particularly in obese population [15–17].
This study was conducted to explore the association
between NAFLD and glucose metabolism with components
of IR which was estimated by indices for both hepatic and
whole body IR.
2.Methods and Materials
2.1. Population Selection. Patients were selected from the
database of 445 individuals with clinically severe obesity that
consecutively underwent laparoscopic gastric bypass surgery
and intra-operative liver biopsy at University of Alabama-
Birmingham between January 2002 and March 2007. NIH
guidelines (BMI > 40kg/m2 or BMI > 35kg/m2 associated
with medical comorbidities) were used to determine surgical
eligibility. Most subjects underwent a 6-month physician-
monitored weight reduction program before being consid-
ered for surgery. Only those subjects were included in the
database who had clinically diagnosis of NAFLD based on
history of alcohol consumption in amounts less than what is
generally considered to be hepatotoxic and absence of other
liver diseases [18]. Alcohol intake (<20gm/day in females
and <40gm/day in males) was assessed separately by both
physician and surgeon who were involved in the patient
care. Preoperatively, all patients had several laboratory tests
done, including hepatitis B and C serology, ceruloplasmin,
iron studies, alpha1-antitrypsin level, and phenotype and
autoimmune markers to exclude various causes of liver
disease. None of the subjects was taking medications such as
methotrexate, amiodarone, tetracycline, high dose estrogen,
tamoxifen, steroids, or calcium channel blockers. For the
present study only those patients were selected from the
database who did not have a past history of DM and were
not taking any medicines for glucose control. OGTT was
doneasapartofpre-operativeevaluationofallsuchpatients.
The patients did not undergo any specialized diet plan
prior to OGTT which was done 113 ± 71 days prior to
the procedure. From the selected 232 patients who did not
have known DM and who underwent OGTT, 169 patients
were selected in whom fasting and 2 hours postload levels of
both glucose and insulin were documented. 56 patients were
further excluded who were diagnosed as diabetic according
to ADA guidelines (fasting glucose >126mg/dl or 2 hours
glucose >200mg/dl) after OGTT. Finally, 113 non-diabetic
morbidly obese subjects were included in this study for
comparison of surrogate markers of hepatic and whole body
IR. All subjects had previously provided informed consent
and protocol of the study was approved by the Human
Investigative Committee of the University of Alabama at
Birmingham.
2.2.Pre-OperativeEvaluation. Laboratoryevaluationinclud-
ed routine liver tests panel (AST, ALT, total bilirubin,
alkalinephosphatase,totalprotein,andalbumin),lipidpanel
(cholesterol, TAG, HDL, and LDL), and complete blood
count. These tests were done on the same day. OGTT was
done according to the standard ADA guidelines. In overnight
fasting state, all patients were given 75gm glucose dissolved
in water and blood was drawn at 0 (fating state), 0.5, 1 and 2
hours interval. Glucose and insulin levels were estimated by
standard laboratory methods. Surrogate markers of IR were
calculated from the fasting (0 hour) and 2 hours insulin and
glucose levels.
T h ef o r m u l a eo fI Ra r eg i v e nb e l o w .
(1) HOMA-IR = [Glucose at 0 hours (mg/dl)]×[Insu-
lin at 0 hours (mIU/L)]/405.
(2) 1/QUICKI = log [Glucose at 0 hours (mg/dl)] × log
[Insulin at 0 hours (mIU/L)].
(3) 1/ISI0,120 = log mean insulin/MCR; where, log
mean insulin = log [(Insulin at 0 hours (mIU/L) +
Insulin at 2 hours (mIU/L))/2] and MCR = m/mean
glucose, m = [75000+(Glucose at 0 hours (mg/L)—
Glucose at 2 hours (mg/L))×0.19×weight (kg)]/120
and mean glucose = [Glucose at 0 hours (mmol/L)+
Glucose at 2 hours (mmol/L)]/2.
(4) 1/WBISI = square root of [Insulin at 0 hours
(mIU/L) × Glucose at 0 hours (mmol/L) × mean
glucose (mmol/L) × mean insulin (mIU/L)]/10,000;
where mean glucose = [Glucose at 0 hours (mmol/
L) + Glucose at 2 hours (mmol/L)]/2 and mean
insulin = [Insulin at 0 hours (mIU/L) + Insulin at
2 hours (mIU/L)]/2.
2.3. Histological Evaluation. Liver biopsies were performed
on the left lobe of liver at the beginning of the operation
using a core biopsy needle (Bard Max-Core, Covington,
GA). The liver biopsy was interpreted by a single pathologist
blinded to all clinical data. NAFLD is typically associated
with macrovesicular fat accumulation in hepatocytes with
nucleus pushed to periphery, giving the classic “signet ring”
appearance. Hepatic inﬂammation in NASH is characterized
by lymphocytic inﬁltration into the hepatic lobules. SteatosisJournal of Obesity 3
was graded according to amount of fat present in the
hepatocytes in biopsy specimen as 0: normal (1%–5%), 1:
mild (6%–33%), 2: moderate (34%–66%), and 3: severe
(67%–100%). The cellular inﬁltration was identiﬁed as
panlobular, portal, or both and subjectively assessed as
mild, moderate, or severe. The pathological diagnosis NASH
was made in accordance with Kleiner et al. criteria [19]
(i.e., steatosis and ballooning degeneration and/or ﬁbrosis
in zone 3) and staging of ﬁbrosis was done in accordance
with the National Institutes of Health sponsored NASH
Clinical Research Network guidelines: stage (1) (1a/b—
mild/moderate zone 3 ﬁbrosis; 1c—zone 1 ﬁbrosis only);
stage (2) both zone 3 and zone 1 ﬁbrosis; stage (3) bridging;
and stage (4) cirrhosis. Steatosis alone (no zone 3 injury or
ﬁbrosis) ± zone 1 (portal/periportal) ﬁbrosis was identiﬁed
as FL. Biopsies showing no or minimal (<5%) steatosis and
absent injury or ﬁbrosis were considered as Normal. Study
populationwasdividedinto3groups;Normal,FLandNASH
on the basis of liver biopsy diagnosis criteria.
2.4. Statistical Analysis. All the indices used in the study
were the measures of Insulin Sensitivity. The values were
inversed to use them as indices of IR. This also helped in
reciprocal transformation of skewed data to symmetrical
distribution and to reliably create conﬁdence intervals. Data
was analyzed as both continuous and categorical variables.
All continuous variables were expressed as Mean ± (SD)
and categorical as Numbers or percentages. Independent
t test and ANOVA were used for normally distributed
continuous variables. Nonparametric tests (Mann-Whitney
and Kruskal-Wallis with post hoc analysis) were applied for
ordinal or continuous variables that showed signiﬁcance on
Kolmogorov-Smirnov test. Categorical variables were ana-
lyzed using Chi-square or Fisher exact tests with correction,
when appropriate. A P value cut-oﬀ was selected to be <.01
to get stronger evidence against null hypothesis. Statistical
analysis was performed by using SPSS (SPSS Inc., Chicago,
IL; V13.0 for windows).
3. Results
Table 1 presents the clinical and biographical data of pop-
ulation which consists of 113 non-diabetic, obese patients
who underwent pre-operative testing and intra-operative
liver biopsy. Table 2 shows histological classiﬁcation study
populations. Biopsy sample was adequate for histological
assessment of NAFLD and comparable among groups.
Population mean age was 39.4 years and BMI was 49kg/m2.
The study population was divided into three groups on
histological basis as already described. FL (51%), NASH
(27%) and Normal (22%) were statistically similar in age,
BMI, gender, and race distribution. Overall there was female
and Caucasian predominance in our population (89%
and 79%, respectively). The means of other biochemical
parameters including LDL, HDL, TAG, and Albumin were
not statistically diﬀerent among the groups. However liver
transaminases (both AST and ALT) were signiﬁcantly ele-
vated in NASH group as compared to both FL and Normal
groups.
Parameters of OGTT were compared among groups as
shown in Table 1. Fasting glucose was comparable among all
the three groups of this non-diabetic population. However
fasting insulin and c-peptide levels were signiﬁcantly higher
in NASH as compared to Normal group only. FL group
was seen in transition between Normal and NASH group.
Fasting c-peptide to insulin ratio was similar among groups
which showed insulin extraction by liver was similar in all
the groups. 2 hours after glucose ingestion insulin levels were
similar among groups but glucose levels were signiﬁcantly
elevated in FL as compared to Normal group only.
The comparison of metabolic status of our study pop-
ulation revealed comparatively large proportion of NAFLD
patients with underlying impaired glucose tolerance as
shown in Table 3. Abnormal glucose tolerance has been
shown to be present in NAFLD in previous studies but
our study further broke NAFLD into biopsy proven FL and
NASH. Among FL, 24% had IGT and 12% had IFG. In
subjects with NASH, 20% and 14% were diagnosed with
IGT and IFG, respectively. Taken together, no signiﬁcant
diﬀerence in the prevalence of IGT or IGF was noted in
the FL and NASH groups. IGT and IFG patients were
signiﬁcantlylessprevalentintheNormalgroup(only7%and
4%, respectively).
Four indices of IR were compared in our study (Table 4).
When compared as NAFLD versus. Normal, all indices
showed statisticallysigniﬁcantdiﬀerenceindicating thatIRis
present in NAFLD irrespective of the spectrum of pathology.
Studypopulationconsistedofseverelyobeseindividualswith
BMI of 49.0 ± (8.0)kg/m2 so the IR values were already
high as shown in other studies [20]. Figure 1 shows further
comparison of these indices along the spectrum of NAFLD.
Fasting-based indices HOMA and QUICKI were statistically
diﬀerent among NASH and Normal group. While OGTT
based whole body IR as measured by ISI0,120 and WBISI were
signiﬁcantly diﬀerent in both NASH and FL group when
compared to Normal.
4. Discussion
IR is an important clinical problem that occurs nearly
in all patients with NAFLD and MetS. The presence of
IR in non-diabetic individuals portends higher risk of
developing NAFLD, DM or cardiovascular disease [21]. In
vivo, IR can be measured directly by sophisticated tests
like glucose clamp techniques and Insulin suppression tests.
However, direct measures of IR are frequently expensive,
time demanding, and labor intensive. For large clinical
studies involving measurement of IR, use of the surrogate
markers is a more practical option. HOMA and QUICKI
estimate IR in fasting state and measure central (hepatic) IR.
Central IR manifests clinically as fasting hyperglycemia due
to unrestrained hepatic gluconeogenesis. Insulin mediates
glucose disposal in the peripheral tissues. This mechanism
is mostly determined by peripheral IR and it has been shown
that the pathways involved in insulin stimulated peripheral
glucose uptake are deranged in patients with MetS [22].
Peripheral IR can be estimated indirectly with the whole
body IR using ISI0,120 and WBISI as surrogate measures.4 Journal of Obesity
Table 1: Population Description. Breakup of study population according to the NAFLD spectrum is shown. Data represents Mean±(SD).
Total Normal FL NASH
N 113 26 58 29
Age (years) 39.4 ± (8.3) 38.4 ± (11.0) 38.9 ± (7.2) 41.4 ± (7.6)
Gender (males/females) 12/101 1/25 5/53 6/23
Race (Caucasian white/AA) 89/24 18/8 46/12 25/4
BMI (kg/m2) 49.0 ± (8.0) 47.0 ± (6.4) 49.1 ± (8.2) 50.5 ± (8.7)
Fasting c-peptide (ng/ml)
1 4.4 ± (1.6) 3.7 ± (1.6) 4.3 ± (1.6) 5.1 ± (1.4)
Insulin (mIU/L) at 0 hours in OGTT 1 23.5 (14.2) 17.3 (7.6) 22.9 (11.2) 30.3 (20.3)
Fasting c-peptide to insulin ratio 0.22 (0.1) 0.24 (0.1) 0.22 (0.1) 0.21 (0.1)
Insulin (mIU/L) at 2 hours in OGTT 95.1 (73.4) 63.7 (53.2) 106.1 (80.5) 101.2 (68.1)
Glucose (mg/dl) at 0 hours in OGTT 99.4 (10.4) 95.5 (8.6) 99.9 (10.6) 101.8 (10.9)
Glucose (mg/dl) at 2 hours in OGTT
2 119.3 (29.9) 104.5 (26.3) 125.4 (30.7) 120.3 (27.7)
AST (U/L)
3 22.8 (8.6) 21.4 (8.4) 20.7 (6.1) 28.4 (10.9)
ALT (U/L)
3 27.2 (15.8) 25.4 (17.6) 22.7 (7.8) 37.6 (21)
Albumin (g/dl) 4.5 (8.8) 3.6 (0.2) 5.3 (12.1) 3.8 (0.3)
Total Cholesterol (mg/dl) 191.6 (32.2) 189.0 (23.9) 187.3 (34.4) 202.6 (32.7)
TAG (mg/dl) 139.4 (104) 104.2 (51.3) 130.8 (71.2) 189.0 (164)
HDL (mg/dl) 44.4 (10.2) 48.0 (10.4) 43.5 (8.6) 42.8 (12.3)
LDL (mg/dl) 122.2 (29) 122.7 (16.9) 120.4 (31.3) 125.3 (33.4)
No. of portal tracts in biopsy 12.1 (4.6) 11.0 (5.7) 11.5 (5.3) 13.3 (3.5)
1 = P<. 01 for NASH as compared to Normal only, 2 = P<. 01 for FL as compared to Normal only, 3 = P<. 01. for NASH as compared to both FL and
Normal.
Table 2: Histological classiﬁcation of study population for the spectrum of NAFLD.
NN
Normal 26
FL (hepatic steatosis) 58
(i) Without Portal Fibrosis 37
21
(ii) With Portal Fibrosis (1c)
NASH (steatosis + ballooning/zone3 ﬁbrosis) 29
(iii) With ballooning 25
(1) No ﬁbrosis (ballooning only) 3
(2) With ﬁbrosis 22
(a) Stage 1a & 2 15
(b) IPF (1c) 3
(c) Advanced ﬁbrosis 3







Although changes in hepatic IR parallel with changes in
peripheral IR frequently, it has been shown that signiﬁcant
number of individuals with normal or near normal hepatic
IR have impaired peripheral IR [23].
In the present study, we assessed the association of
NAFLD and the components of IR among morbidly obese
individuals. The study suggests that NAFLD is related to
an increase in IR and there are comparative diﬀerences in
hepatic and whole body IR along the spectrum of NAFLD.
Importantly,thesediﬀerenceswereidentiﬁedbyusingsimple
non-invasive methods. The presence of IR in NAFLD and































































Figure 1: Box plot analysis of surrogate markers of hepatic and whole body insulin resistance along the spectrum of NAFLD. (a) HOMA-
IR and (b) 1/QUICKI calculated from fasting insulin and glucose levels represent hepatic (central) insulin resistance. (c) 1/ISI0,120 and (d)
1/WBISI calculated from both fasting and 2 hours postglucose challenge insulin and glucose levels represent whole body insulin resistance,
which is composite of hepatic and peripheral insulin resistance. Groups were compared by nonparametric test (Kruskal-Wallis H test) and
post hoc corrections. ∗=P<. 01 and # = P<. 05.
and direction of this connection still remains a matter
of debate. Our study conﬁrms the presence of IR among
morbidly obese NAFLD patients. A signiﬁcant number of
these obese subjects with IR had normal liver biopsies.
Although sampling error is a possibility, this observation
points out the importance of other factors which might be
involved in pathogenesis of NAFLD. DM is the advanced
form of IR and has a strong association with NAFLD. To
eliminate its confounding eﬀect, we selected to investigate
only the non-diabetic individuals based on ADA guidelines.
Thus, all included subjects had fasting glucose levels in
non-diabetic range. The study population was divided into
three groups of Normal, FL, and NASH according to the
well accepted histological deﬁnition of NAFLD. The NASH
g r o u pd e m o n s t r a t e de l e v a t e df a s t i n gI n s u l i nl e v e l sd u et o
underlying hepatic IR and this was not a consequence of
decreased insulin extraction, which occurs in advanced liver
ﬁbrosis. In FL, there was a sustained postload hyperglycemia,
secondary to peripheral IR and inability to eﬃciently move
glucose into peripheral tissues.6 Journal of Obesity
Table 3: Metabolic status of population from 2 hours oral glucose
load testing.
Normal FL NASH Total
Normoglycemic 23 37 19 79
Impaired Fasting Glucose (IFG) 2 7 4 13
Impaired Glucose Tolerance (IGT) 1 14 6 21
26 58 29 113
Normoglycemic = Fasting glucose <110 and 2 hours glucose <140,
Impaired Fasting Glucose = Fasting glucose 110 to 126, Impaired glucose
tolerance = 2 hours glucose 140 to 200, Units = mg/dl.
Table 4: Indices of Insulin resistance calculated from insulin and
glucose levels during OGTT. Data represented as Mean±(SD).∗
Total Normal NAFLD
N 113 26 87
HOMA-IR 5.882 (3.818) 4.105 (1.924) 6.413 (4.083)
1/QUICKI 3.303 (0.252) 3.177 (0.217) 3.341 (0.251)
1/ISI0,120 0l.018 (0.007) 0.015 (0.005) 0.019 (0.007)
1/WBISI 0.385 (0.24) 0.252 (0.139) 0.425 (0.25)
∗=P <. 01 for all four indices of insulin resistance for NAFLD as
compared to Normal by non-parametric test (Mann-Whitney test).
The important ﬁnding in this study was the gradual
increase in the whole body IR and its component—hepatic
IR along the spectrum on NAFLD. Whole body IR was
signiﬁcantly diﬀerent in both FL and NASH groups when
compared to Normal. However, the diﬀerence in hepatic IR
became signiﬁcant only in NASH as compared to Normal.
Thus, indirectly—peripheral IR signiﬁcantly increased in
FL as compared to Normal. This observation leads to the
assumption that FL is a manifestation of peripheral IR but
not hepatic IR. NASH is associated with increase in hepatic
IR and further worsening of whole body IR. Similar ﬁndings
were also observed in hypertensive individuals where up to a
40% increase in peripheral IR was noted in the studies [24].
Limitations in this study included intraindividual varia-
tion of WBISI and ISI0,120 secondary to signiﬁcant variations
in 2 hours glucose and insulin levels in individuals subjected
to OGTT at diﬀerenttimes[25].Variousmedicationssuchas
beta blockers and diuretics have been shown to inﬂuence IR
in hypertensive populations [26] .T h e r ei sas e l e c t i o nb i a si n
this study as the cohort investigated included only morbidly
obese patients who were undergoing gastric bypass surgery
and this may not be extrapolated to the general obese pop-
ulation. The subjects investigated comprised predominantly
females and Caucasians. Liver biopsy sampling error and
observer variability were also important factors pertaining to
our study [27].
In summary, by using simple non-invasive measures we
showed that NAFLD is associated with worsening of whole
body IR. This increase in IR is signiﬁcant only in peripheral
tissues in FL population. Possibly, this leads to further
channeling of lipids and glucose to the liver and subsequent
development of hepatic IR. Hepatic IR results in a sustained
postprandial hyperglycemia and hyperinsulinemia—which
are important factors involved in cellular injury and ﬁbrosis
characteristic of NASH and progression of NAFLD. Further
studies are needed for more elaborative evaluation of these
components of IR in NAFLD in an eﬀort to identify the
pathogenesis of progression of this disease.
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